natgillin/translations-raw huggingface dataset:
The CHMP decided that PritorPlus’s benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on telmisartan alone.
Inimravimite komitee otsustas, et PritorPlusi kasulikkus nende essentsiaalse hüpertensiooniga patsientide ravis, kelle vererõhku ei saa ainult telmisartaaniga piisavalt reguleerida, on suurem kui ravimiga kaasnevad riskid.
The CHMP decided that Pritor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Pritori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Prolia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Prolia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that ProQuad’s benefits are greater than its risks and recommended that it be given marketing authorisation for use in children above 12 months of age, noting that a second vaccination against chickenpox should be given for full protection against the disease.
Inimravimite komitee otsustas, et ProQuadi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa kasutamiseks üle 12-kuustel lastel, märkides, et täieliku kaitse tagamiseks tuulerõugete vastu tuleb teha teine tuulerõugete vastane vaktsineerimine.
The CHMP decided that Protaphane’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Protaphane kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Protelos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Protelose kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Protopic’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Protopicu kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rapamune’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rapamune kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rapilysin’s benefits are greater than its risks for and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rapilysini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rapiscan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rapiscani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rasilamlo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rasilamlo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rasilez HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rasilez HCT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rebetol’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rebetoli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rebif’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rebifi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Regranex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Regranexi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Relistor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Relistori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Remicade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Remicade kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Renagel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Renageli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Replagal’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Replagali kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Resolor’s benefits are greater than its risks and recommended that it be given marketing authorisation..
Inimravimite komitee otsustas, et Resolori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Revlimid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Revlimidi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Revolade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Revolade kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rienso’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rienso kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rilutek’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Riluteki kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Riluzole Zentiva’s benefits are greater than its risks to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis.
Inimravimite komitee otsustas, et Riluzole Zentiva kasulikkus eluea pikendamisel või amüotroofilise lateraalskleroosiga patsientide mehaanilise ventilatsiooni ajal on suurem kui sellega kaasnevad riskid.
The CHMP decided that Riprazo HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Riprazo HCT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ristaben’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ristabeni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ristfor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ristfori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that RoActemra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et RoActemra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Rotarix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Rotarixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that RotaTeq’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et RotaTeqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Ruconest’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ruconesti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ryzodeg’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ryzodegi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Scintimun’s benefits are greater than its risks.
Inimravimite komitee otsustas, et Scintimuni kasulikkus ületab kaasnevaid riske.
The CHMP decided that Sebivo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Sebivo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Selincro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Selincro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Sifrol’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Sifroli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Siklos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Siklose kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Silgard’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Silgardi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Silodyx’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Silodyxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Simponi’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Simponi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that SonoVue’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et SonoVue kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Sprimeo HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Sprimeo HCT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Sprycel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Spryceli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Stalevo’s benefits are greater than its risks for the treatment of patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment.
Inimravimite komitee otsustas, et Stalevo kasulikkus on suurem kui sellega kaasnevad riskid kasutamisel selliste Parkinsoni tõvega patsientide ravis, kellel esineb annuse toime lõpus motoorikakõikumisi, mida ei ole võimalik stabiliseerida levodopa/dopadekarboksülaasiinhibiitori raviga.
The CHMP decided that Stocrin’s benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents, and children three years of age and older.
Inimravimite komitee otsustas, et Stocrini kasulikkus selle kasutamisel HIV-nakkusega täiskasvanutel, noorukitel ja vähemalt 3-aastastel lastel koos teiste viiruseravimitega on suurem kui sellega kaasnevad riskid.
The CHMP decided that Sustiva’s benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents and children three months of age and older.
Inimravimite komitee otsustas, et Sustiva kasulikkus selle kasutamisel HIV-nakkusega täiskasvanutel, noorukitel ja vähemalt 3-kuustel lastel koos teiste viiruseravimitega on suurem kui sellega kaasnevad riskid.
The CHMP decided that Sutent’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Sutenti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Sycrest’s benefits are greater than its risks and recommended that it be given marketing authorisation for the treatment of moderate to severe manic episodes in patients with bipolar disorder.
Inimravimite komitee otsustas, et Sycresti kasulikkus mõõdukate kuni raskete maaniaepisoodide ravis bipolaarse meeleoluhäirega patsientidel on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Synagis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Synagise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that TachoSil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et TachoSili kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tamiflu’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Tamiflu kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tarceva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Tarceva kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tasigna’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Tasigna kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tasmar’s benefits are greater than its risks in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other COMT inhibitors.
Inimravimite komitee otsustas, et Tasmari kasulikkus selle kasutamisel koos levodopa/benserasiidi või levodopa/karbidopaga patsientidel, kelle idiopaatiline Parkinsoni tõbi ja seisundite vaheldumine allub levodopa ravile, kuid kellel ei teki teistele katehhool-O-metüültransferaasi inhibiitoritele ravivastust või kellele need ravimid ei sobi, on suurem kui Tasmariga kaasnevad riskid.
The CHMP decided that Taxotere’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Taxotere kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Temodal’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Temodali kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tesavel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee järeldas, et Tesaveli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Teysuno’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Teysuno kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that the benefits of Eliquis are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Eliquise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that the benefits of Ioa are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ioa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that the benefits of Soliris are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Solirise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that the benefits of Somavert are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Somaverti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that the medicine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ravimi Methylthioninium chloride Proveblue kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that the vaccine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Pumarixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimile müügiloa.
The CHMP decided that the vaccine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et vaktsiini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
The CHMP decided that Thyrogen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Thyrogeni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tobi Podhaler’s benefits are greater than its risks, since it is effective at treating lung infection in cystic fibrosis patients and given its added convenience for patients.
Inimravimite komitee otsustas, et Tobi Podhaleri kasulikkus on suurem kui sellega kaasnevad riskid, sest see on efektiivne kopsuinfektsiooni ravis tsüstilise fibroosiga patsientidel ja seda on mugav kasutada.
The CHMP decided that Torisel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Toriseli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Toujeo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Toujeo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Toviaz’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Toviazi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tracleer’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Tracleeri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Travatan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Travatani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tresiba’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Tresiba kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Trisenox’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Trisenoxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Tygacil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Tygacili kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Tyverb’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Tyverbi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The CHMP decided that Urorec’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Uroreci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Vaniqa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Vaniqa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Vantavo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Vantavo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The CHMP decided that Velcade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Velcade kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Velmetia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Velmetia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Ventavis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ventavise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Vfend’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Vfendi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Viagra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Viagra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Vidaza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Vidaza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Vimpat’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Vimpati kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The CHMP decided that Viracept’s benefits are greater than its risks in antiviral combination treatment of HIV-1 infected adults, adolescents and children of three years of age and older.
Inimravimite komitee otsustas, et Viracepti kasulikkus selle kasutamisel HIV1 nakkusega täiskasvanutel, noorukitel ja vähemalt 3-eaastastel lastel koos teiste viiruseravimitega on suurem kui sellega kaasnevad riskid.